Content continues after advertisement

Research Note: Benazepril in Cats with Heart Disease

Cardiology

|
October 2020

Sign in to Print/View PDF

There are no well-controlled prospective clinical trials that provide evidence of the benefit of any particular medication in feline heart disease. This prospective blinded clinical trial compared the angiotensin-converting enzyme inhibitor benazepril (mean dosage, 0.7 mg/kg once daily; range, 0.5-1.0 mg/kg once daily) with placebo given once daily for up to 2 years. Client-owned cats (n = 151) with confirmed heart disease of various etiologies with or without clinical signs of congestive heart failure were included. Benazepril was found to be well-tolerated; however, no significant differences in time to treatment failure, quality-of-life scores, or echocardiographic measurements were identified between the groups. However, because there were several important limitations of this study, no widespread conclusions should be made regarding potential treatment benefits.

Source

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | Privacy Policy | Acceptable Use Policy